Cellular mechanisms for trazodone-induced cardiotoxicity

Introduction

Depressive disorders acting on the autonomic neurocardiac system may occur in patients with heart disease and are associated with cardiovascular mortality. ^{1 –4} First-generation antidepressants, such as tricyclic antidepressants (TCAs) were demonstrated to have fewer cardiovascular side effects; however, their broad mechanisms of action led to unwanted ventricular arrhythmias and sudden cardiac death, resulting in their removal from the market. ^5,6 To overcome the cardiotoxicity of first-generation antidepressants, second-generation antidepressants, such as selective serotonin reuptake inhibitors ^{7 –9} and the selective 5-HT₂ receptor antagonists and reuptake inhibitors (SARIs), which simultaneously act as postsynaptic serotonin receptor antagonists and presynaptic serotonin reuptake inhibitors, ^{10 –12} were introduced. These drugs are as effective as TCAs, but have higher safety and tolerability profiles. Thus, they are preferred over first-generation antidepressants.

Although trazodone, a tetracyclic SARI, is known to have fewer cardiovascular side effects than TCAs, ¹³ an increasing number of trazodone studies have raised concerns regarding its cardiac safety. Several previous studies showed that trazodone inhibits human ether-a-go-go related gene (hERG) channels by interacting at the aromatic binding site of Y652 and F656 in the S6 domain of hERG. ^14,15 Trazodone also inhibits outward potassium ion (K⁺) channels, which includes transient outward K currents and transiently, rapidly inactivating (voltage-gated potassium) Kv channels . ^16,17 In addition, trazodone was reported to cause QT prolongation and torsade de pointes at both therapeutic doses ^18,19 and overdose levels. ^20,21 Although the likely mechanism for drug-induced long QT syndrome (LQTS) is the interaction of trazodone with KCNH2-encoded hERG K channels, ^15,22 additional genes associated with LQTS can also cause life-threatening cardiac arrhythmias. ²³ Mutations in genes encoding cardiac ionic channels can disrupt the fine balance of ionic currents that shape the action potential (AP) and may lead to life-threatening arrhythmias. For example, mutations to the KCNQ1/KCNE1-encoded slow component of the delayed rectifying K current (I_Ks) channel, KCNH2-encoded rectifier potassium (I_Kr) channel, and SCN5A-encoded inward sodium (Na) current (I_Na) channel can cause LQT1 or LQT5, LQT2 or LQT6, and LQT3, respectively. ^{24 –26}

Cardiac electrophysiological assessment of the SARI trazodone is necessary to identify the mechanisms underlying its cardiovascular side effects; however, the effect of trazodone on cardiac APs, mediated by depolarization and repolarization via ion channels, remains unclear. To elucidate the cellular mechanism of trazodone-induced cardiac adverse events, we investigated the effects of trazodone on electrophysiological cardiac characteristics using the whole-cell patch clamp technique. We evaluated the effect of trazodone on APs in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), which express the major cardiac ion channels and recapitulate spontaneous mechanical and electrical activity similar to adult cardiomyocytes. ^{27 –30} We further evaluated the effect of trazodone on major ion channels, including I_Kr, I_Ks, and I_Na, in human embryonic kidney (HEK293) cells overexpressing single ion channels and calcium ion (Ca⁺) current (I_Ca) in hiPSC-CMs. The results of these assays provide a cardiac electrical basis for trazodone cardiotoxicity and shed light on the cardiac risk potential of trazodone beyond the current gold standard assay for hERG.

Methods

Results

Effects of trazodone on AP waveforms in hiPSC-CMs

To assess whether the changes in cardiac AP properties were due to the effect of trazodone, we obtained current-clamp recordings in hiPSC-CMs (Figure 1). A spontaneous beating activity was recorded and AP-related parameters were quantified as the control condition in hiPSC-CMs (n = 21). The maximum diastolic potential (MDP), maximum upstroke velocity (V_max), total amplitude (TA), AP duration at 90% (APD₉₀), and at 60% (APD₆₀) waveforms were analyzed and only ventricular CMs that had an AP duration longer than 300 ms were included in the analysis. The representative AP traces in control conditions and in the presence of trazodone are shown in Figure 1(a). The average from five recorded APs was analyzed at each test concentration and dose–response studies indicated that APs were completely inhibited after treatment with 100 μM trazodone (n = 3, data not shown). Trazodone prolonged APD₉₀ and APD₆₀ at 3 μM and early after depolarizations (EADs) were induced by 10 μM trazodone, suggesting that trazodone affects the AP waveforms of hiPSC-CMs in a concentration-dependent manner (Figure 1(a)). The AP-related parameters showed no significant effect from trazodone on the MDP and TA (n = 5, Figure 1(b) and (d)); however, a dose-dependent dramatic decrease in V_max was caused by trazodone (n = 5, Figure 1(c)). Further, trazodone prolonged the APD and induced EADs in a concentration-dependent manner (n = 5, Figure 1(e) and (f)). These results demonstrated that trazodone significantly reduced AP V_max prolonging their 90% and 60% durations.

OPEN IN VIEWER

Figure 1.

Cardiac actions of the SARI trazodone on action potential waveforms in hiPSC-CMs. (a) Representative traces induced by 1 μM trazodone. Representative traces show the typical waveform of EAD induced by 3 and 10 μM trazodone. (b) to (f), Normalized AP parameters in control and in the presence of trazodone. MDP: maximum diastolic potential; V_max: maximum upstroke velocity; TA: total amplitude; APD₉₀: action potential duration at 90% repolarization; APD₆₀: action potential duration at 60% repolarization (mean ± SEM, *p < 0.05, **p < 0.01); SARI: selective 5-HT₂ receptor antagonists and reuptake inhibitor; hiPSC-CM: human-induced pluripotent stem cell-derived cardiomyocyte; EAD: early after depolarization; AP: action potential.

Effects of trazodone on cardiac repolarization-related currents: I_Kr and I_Ks in HEK293

To investigate the cellular mechanism underlying the effects of trazodone on repolarization-related currents, KCNH2-encoded fast components of the delayed I_Kr current and KCNQ1/KCNE1-encoded slow components of the delayed rectifier K current (I_Ks) were recorded using voltage-clamp recordings in HEK293 cells. The fast and slow components of the K channel-specific outward currents (I_Kr and I_Ks, respectively) were activated by each step protocol. Trazodone inhibited the I_Kr peak amplitude in a concentration-dependent manner (Figure 2(a)) and produced a high affinity for I_Kr with an IC₅₀ value of 2.83 ± 0.04 μM (Figure 2(b), n = 3). Ten micromoles of trazodone (Figure 2(c)) completely blocked the peak I_Kr current density, but it did not affect the activation- and inactivation-state I-V relationships (Figure 2(d) and (e), n = 3). Trazodone also inhibited the peak amplitude of I_Ks in a concentration-dependent manner (Figure 3(a)), but had a low affinity for I_Ks with an IC₅₀ value of 67.5 ± 0.05 μM (Figure 3(b), n = 3). Trazodone at 300 μM completely blocked the peak I_Ks current density but did not affect the I-V relationships (n = 3, data not shown). These results indicated that trazodone has a higher inhibitory potency on I_Kr than I_Ks in HEK293.

OPEN IN VIEWER

Figure 2.

Effect of the SARI trazodone on I_Kr in HEK293. (a) Representative traces demonstrating the effect of trazodone on HEK293 I_Kr at doses of 0.1, 0.3, 1, 3, and 10 μM, respectively. (b) Dose–response relationship of trazodone, providing an IC₅₀ value of 2.83 ± 0.04 μM (mean ± SEM). (c) Representative I-V traces of I_Kr in control cells (top) and in the presence of trazodone (bottom). (d) Activation-state I-V relationships of I_Kr in control and in the presence of trazodone (mean ± SEM, *p < 0.05, **p < 0.01). (e) Inactivation-state I-V relationships of I_Kr in control and in the presence of trazodone (mean ± SEM, *p < 0.05, **p < 0.01). SARI: selective 5-HT₂ receptor antagonists and reuptake inhibitor; IC₅₀: half-maximal inhibitory concentration; I-V: current–voltage.

OPEN IN VIEWER

Figure 3.

Effect of the SARI trazodone on I_Ks in HEK293. (a) Representative traces demonstrating the effect of trazodone on HEK293 I_Ks at doses of 1, 3, 10, 30, 100, and 300 μM, respectively. (b) Dose–response relationship of trazodone, providing an IC₅₀ value of 67.5 ± 0.05 μM (mean ± SEM). SARI: selective 5-HT₂ receptor antagonists and reuptake inhibitor; IC₅₀: half-maximal inhibitory concentration.

Effects of trazodone on cardiac depolarization-related currents: I_Na in HEK293 and I_Ca in hiPSC-CMs

To investigate the effect of trazodone on the depolarization-related currents, the SCN5A-encoded inward Na current (I_Na) was recorded in HEK293 and the Ca²⁺-specific inward current (I_Ca) was recorded in hiPSC-CMs. Trazodone inhibited the peak amplitude of I_Na in a concentration-dependent manner (Figure 4(a)) but produced a slightly high affinity for I_Na with an IC₅₀ value of 11.07 ± 0.09 μM (Figure 4(b), n = 4). Trazodone at 100 μM completely blocked the peak I_Na current density but did not affect the I-V relationships (n = 3, data not shown). We verified the I_Ca of hiPSC-CMs using a selective Ca²⁺ channel antagonist, nifedipine, which inhibited the peak amplitude of I_Ca in a concentration-dependent manner with an IC₅₀ value of 0.84 μM (n = 4, data not shown). Trazodone inhibited the I_Ca peak amplitude in a concentration-dependent manner (Figure 5(a)) but showed a low affinity for I_Ca with an IC₅₀ value of 19.05 ± 0.13 μM (Figure 5(b), n = 3). Trazodone at 300 μM completely blocked the peak I_Ca current density, but it did not affect the I-V relationships (n = 4, data not shown). These results indicated that trazodone is more effective in inhibiting I_Na in HEK293 than I_Ca in hiPSC-CMs.

OPEN IN VIEWER

Figure 4.

Effect of the SARI trazodone on I_Na in HEK293. (a) Representative traces demonstrating the effect of trazodone on HEK293 I_Na at doses of 1, 3, 10, 30, and 100 μM, respectively. (b) Dose–response relationship of trazodone, providing an IC₅₀ value of 11.07 ± 0.09 μM (mean ± SEM). SARI: selective 5-HT₂ receptor antagonists and reuptake inhibitor; IC₅₀: half-maximal inhibitory concentration.

OPEN IN VIEWER

Figure 5.

Cardiac actions of the SARI trazodone on I_Ca in hiPSC-CMs. (a) Representative traces demonstrating the effect of trazodone on hiPSC-CMs I_Ca at doses of 1, 3, 10, 30, 100, and 300 μM, respectively. (b) Dose–response relationship of trazodone, providing an IC₅₀ value of 19.05 ± 0.13 μM (mean ± SEM). SARI: selective 5-HT₂ receptor antagonists and reuptake inhibitor; IC₅₀: half-maximal inhibitory concentration; hiPSC-CM: human-induced pluripotent stem cell-derived cardiomyocyte.

Discussion

Most clinical studies using SARIs suggest that trazodone has significant advantages over first-generation antidepressants; however, recent studies indicate that trazodone may have cardiovascular side effects. ^{18 –21} Several clinical studies suggest that cardiotoxicity is induced via trazodone acting on hERG channels, which are involved in cardiac repolarization, thereby inducing QT prolongation and ventricular arrhythmias. ^15,22 Although it is widely accepted that ventricular arrhythmias are primarily caused by I_Kr inhibition, drug-induced inhibition of I_Kr does not show a clear correlation with QT prolongation risk and the occurrence of arrhythmias. ³¹ Thus, further studies are required to evaluate whether trazodone affects cardiac APs during ion channel depolarization or repolarization beyond the hERG.

In this study, we hypothesized that trazodone modulates cardiac APs, which is controlled by interactions between depolarizing (I_Na and I_Ca) and repolarizing (I_Kr and I_Ks) ion channels, including the hERG channel. Our cardiac electrophysiological studies demonstrated that trazodone modulated the AP waveforms of hiPSC-CMs by dose dependently inducing APD₉₀ and APD₆₀ prolongation and decreasing V_max, without changing the MDP and TA. Trazodone completely inhibited APs at 100 μM (data not shown) and EADs were induced at 10 μM (Figure 1). As in previous studies, our results indicated that trazodone inhibited the hERG channel (Figure 2). Moreover, other major cardiac ion currents, including I_Ks (Figure 3), I_Na (Figure 4), and I_Ca (Figure 5), were also dose dependently inhibited by trazodone.

One potential mechanism by which trazodone dose dependently prolongs APD₉₀ (Figure 1(e)) is inhibition of repolarization-related K⁺ currents. Trazodone inhibited I_Kr with an IC₅₀ value of 2.83 ± 0.04 μM and blocked hERG by about 80% at a dose of 10 μM (Figure 2(b)). Trazodone also inhibited I_Ks but had a lower inhibitory potency, and I_Ks inhibition was approximately 30% at 10 μM trazodone (IC₅₀ > 10 μM, Figure 3(b)). The other possible mechanism by which trazodone dose-dependently prolongs APD₆₀ (Figure 1(f)) is correlated with the activation of Ca²⁺ currents. Trazodone adversely inhibited I_Ca; however, its inhibitory potency on I_Ca was low; I_Ca inhibition was about 40% at 10 μM trazodone (IC₅₀ > 10 μM, Figure 5(b)). The effects of trazodone on V_max (Figure 1(c)), which is an indirect indicator of the fast Na⁺ channel, suggest that it potently inhibits I_Na. Trazodone had a slightly high inhibitory potency and blocked I_Na by about 50% at 10 μM (IC₅₀ > 10 μM, Figure 4(b)). Although the net effect of trazodone on AP properties depends on the overall balance between inward and outward currents, the IC₅₀ value of I_Kr was 30-, 5-, and 10-fold more potent than I_Ks, I_Na, and I_Ca, respectively. These results suggest that trazodone potently and dose-dependently inhibits cardiac voltage-dependent ion channels, with its greatest effect occurring on hERG.

Cardiotoxicity testing, including in vitro assays and in vivo animal models, is an important part of preclinical drug evaluation prior to first-in-human clinical trials; however, many drugs that have passed animal tests have unanticipated cardiotoxicity during clinical phases. ^{32 –34} Therefore, the development of a sensitive in vitro model suitable for cardiac safety testing is extremely important. The most well-known electrophysiological studies use immortalized mammalian cell lines overexpressing single ion channel; however, these are not representative of native human cardiomyocytes. Although the IC₅₀ value of trazodone for I_Kr is important to gaining insight into the drug’s actions on APs, its additional inhibitory actions on Na⁺ and Ca²⁺ channels may exert other antiarrhythmic and proarrhythmic actions. Therefore, it is difficult to correlate in vitro IC₅₀ values with the predictive arrhythmogenic properties of a drug.

Recently, hiPSC-CMs have been established as an attractive model for cardiac toxicity testing, as they express the major ion channels and recapitulate spontaneous mechanical and electrical activity, similar to adult cardiomyocytes. ^{27 –30} We evaluated the effect of trazodone on AP parameters in hiPSC-CMs, which is a physiologically relevant preclinical evaluation of drug-induced ventricular arrhythmias. Our findings indicated that hiPSC-CMs are sensitive and accurate predictors of trazodone-induced cardiotoxicity. Trazodone-induced prolonged APD may result from the complex interactions between Na⁺, Ca²⁺, and K⁺ currents, though its profound effect on ventricular APD may be related to its ability to regulate K⁺ channels. Although hiPSC-CMs have opened new horizons for drug screening and detecting undesired proarrhythmic side effects of preclinical drugs, ^{35 –37} they may still show gene expression profiles similar to immature human fetal cardiomyocytes. ^{38 –40} The electrophysiological properties of partially mature hiPSC-CMs have mixed subtypes and restricted functionality compared to human adult cardiomyocytes, which can limit their application in drug screening. ^{41 –43} To overcome this constraint, it will be crucial to develop a maturation protocol for hiPSC-CMs and verify and validate the obtained results in the initial screening steps.

Trazodone was developed as 150 mg and 300 mg caplets for once daily administration and known to be well absorbed after oral administration without selective localization in any tissue. ⁴⁴ In a clinical setting, the plasma concentration of trazodone increases proportionally after administration of a single dose or under steady-state conditions. ^45,46 Fagiolini et al. reported that plasma concentration (C_max) of trazodone reached 1.2 μM after a single oral dose of 100 mg. Steady state C_max of trazodone were 3.1 μM after administration of 100 mg three times a day, and 1.8 μM after 300 mg administration once daily for 1 week. ⁴⁴ When compared with the potency of hERG inhibition (IC₅₀, 2.83 μM), the C_max overlaps with the ranges of inhibitory effects on hERG.

Collectively, our in vitro studies indicated that trazodone dose-dependently inhibits all of the major cardiac ion channels, including hERG. The prolonged APD and decreased V_max due to trazodone are mainly the result of hERG and Na⁺ inhibition and hiPSC-CMs are sensitive models for detecting the repolarization and depolarization delay induced by trazodone. Our understanding of the cellular mechanisms of trazodone-induced cardiac toxicity may aid in preclinical trials, better dose selection, and reduction of unexpected, life-threatening cardiac arrhythmias.